mProX™ Human SLC22A2 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-0922-KX1562	Magic™ Human SLC22A2 in Vitro Drug screening assay	Human	Caco-2, MDCK, HEK293, CHO, membrane vesicles, and various transfected cells lines	Activity Assay (High throughput screening assays; Large scale single dose, duplicate profiling; IC50 profiling; Ki determination assay; Substrate determination assay )

Product Information

Target Protein

SLC22A2

Target Family

SLC Transporter

Target Protein Species

Human

Host Cell Type

HCC; CHO-K1; HEK293

Target Classification

Transporter Cell Lines

Target Research Area

Diabetes Research; Metabolic Research

Related Diseases

Carnitine Deficiency; Systemic Primary; Type 1 Diabetes Mellitus

Gene ID

6582

UniProt ID

O15244

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

A protein called solute carrier family 22 member 2 (OCT2, or organic cation transporter-2) is encoded by the SLC22A2 gene in humans. Numerous endogenous small organic cations, as well as a broad range of medications and environmental pollutants, must be eliminated by the action of polyspecific organic cation transporters found in the liver, kidney, intestine, and other organs. On chromosome 6, this gene is part of a cluster including three other related cation transporter genes. The encoded protein is a plasma integral membrane protein with twelve putative transmembrane domains. Primarily located in the kidney, it could potentially mediate the initial stage of cation reabsorption. The customized SLC22A2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Sharon

The mouse SLC22A2 cell line is of superior quality, and I am confident in its reliability. Dec 06 2022

chat Verified Customer

chat William

I recently purchased the SLC22A2 overexpression cell line, and it has exceeded my expectations. Apr 07 2021

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Expression analysis in normal and tumor tissues.

By using confocal laser scanning microscopy, the protein expression of SLC22A1/OCT1, SLC22A2/OCT2, and SLC22A3/OCT3 (green) was examined in HCC tumor tissue and compared with histologically normal liver tissue obtained from patients who did not have hepatocellular carcinoma (HCC). To find the proteins SLC22A1, SLC22A2, and SLC22A3, certain antibodies were employed.

Ref: Schaeffeler, Elke, et al. "DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma." Genome medicine 3.12 (2011): 1-1

Pubmed: 22196450

DOI: 10.1186/gm298

Research Highlights

In particular, OCT2-altered expression in primary and metastatic cancer cells relative to surrounding tissues could be utilized in RCC imaging to improve the sensitivity of detection for tiny metastatic lesions, a significant clinical hurdle in early RCC staging.
Visentin, Michele, et al. "Fluorocholine transport mediated by the organic cation transporter 2 (OCT2, SLC22A2): implication for imaging of kidney tumors." Drug Metabolism and Disposition 46.8 (2018): 1129-1136.
Pubmed: 29794161 DOI: 10.1124/dmd.118.081091

By predicting the response to metformin and other classes of T2DM medications, the study's findings potentially improve clinical outcomes and personalize treatment.
Al-Eitan, Laith N., et al. "Metformin pharmacogenetics: effects of SLC22A1, SLC22A2, and SLC22A3 polymorphisms on glycemic control and HbA1c levels." Journal of personalized medicine 9.1 (2019): 17.
Pubmed: 30934600 DOI: 10.3390/jpm9010017